Literature DB >> 29292480

Agitation thrombolysis and catheter-directed thrombolysis for normotensive patients with acute pulmonary thromboembolism.

Yonghua Bi1,2,3, Zepeng Yu1,2,3, Xinwei Han4,5,6, Jianzhuang Ren1,2,3.   

Abstract

OBJECTIVE: To assess the feasibility, efficacy, and safety of agitation thrombolysis and catheter-directed thrombolysis (AT-CDT) in the treatment of normotensive patients with acute pulmonary thromboembolism (PTE).
METHODS: A total of 37 consecutive patients of normotensive PTE were treated by AT-CDT between October 2011 and January 2016. Clinical outcomes and mortality were evaluated after the treatment, and follow-up was carried out after hospital discharge.
RESULTS: AT-CDT was technically successful in 93.7% (36/37) patients, with one case died from respiratory failure during procedure. The clinical success rate was 91.9% (34/37), one patient died from intracranial hemorrhage 9 days after agitation, and one case showed no improvement. A total of 83.8% (31/37) cases were clinical cured and 8.1% (3/37) cases were relieved during hospitalization. Three cases died of respiratory failure caused by PTE, and two cases died of diseases unrelated to PTE (lung carcinoma/hemoptysis) during a 20-1524 days of follow-up.
CONCLUSION: AT-CDT may be a feasible, effective, and safe treatment for normotensive patients with acute PTE.

Entities:  

Keywords:  Agitation thrombolysis; Catheter-directed thrombolysis; Follow-up; Pulmonary thromboembolism; Thrombolysis

Mesh:

Substances:

Year:  2018        PMID: 29292480     DOI: 10.1007/s11547-017-0848-1

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  18 in total

1.  Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter.

Authors:  T Schmitz-Rode; U Janssens; S H Duda; C M Erley; R W Günther
Journal:  J Am Coll Cardiol       Date:  2000-08       Impact factor: 24.094

2.  The incidence of pulmonary embolism in unexplained sudden cardiac arrest with pulseless electrical activity.

Authors:  K A Comess; F A DeRook; M L Russell; T A Tognazzi-Evans; K W Beach
Journal:  Am J Med       Date:  2000-10-01       Impact factor: 4.965

3.  Budd-Chiari syndrome with fresh inferior vena cava thrombosis: agitation thrombolysis and balloon dilation.

Authors:  P-X Ding; Y-D Li; X-W Han; G Wu; S-F Shui; Y-L Wang
Journal:  Vasa       Date:  2011-01       Impact factor: 1.961

4.  Pulmonary embolism as a cause of cardiac arrest: presentation and outcome.

Authors:  I Kürkciyan; G Meron; F Sterz; K Janata; H Domanovits; M Holzer; A Berzlanovich; H C Bankl; A N Laggner
Journal:  Arch Intern Med       Date:  2000-05-22

5.  Systemic Thrombolytic Therapy and Catheter-Directed Fragmentation with Local Thrombolytic Therapy in Patients with Pulmonary Embolism.

Authors:  Julia Klevanets; Vladimir Starodubtsev; Pavel Ignatenko; Olga Voroshilina; Pavel Ruzankin; Andrey Karpenko
Journal:  Ann Vasc Surg       Date:  2017-05-10       Impact factor: 1.466

Review 6.  Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism.

Authors:  Kenneth E Wood
Journal:  Chest       Date:  2002-03       Impact factor: 9.410

7.  Massive pulmonary embolism: treatment with the hydrolyser thrombectomy catheter.

Authors:  M Fava; S Loyola; I Huete
Journal:  J Vasc Interv Radiol       Date:  2000-10       Impact factor: 3.464

8.  Fragmentation of massive pulmonary embolism using a pigtail rotation catheter.

Authors:  T Schmitz-Rode; U Janssens; H H Schild; S Basche; P Hanrath; R W Günther
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

Review 9.  Applications of percutaneous mechanical thrombectomy in pulmonary embolism.

Authors:  Mario Fava; Soledad Loyola
Journal:  Tech Vasc Interv Radiol       Date:  2003-03

Review 10.  Thrombolysis is not warranted in submassive pulmonary embolism: a systematic review and meta-analysis.

Authors:  Naresh Ramakrishnan
Journal:  Crit Care Resusc       Date:  2007-12       Impact factor: 2.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.